Development Drug Trials Drugs Life Science 
Drug Discovery World
MARCH 7, 2023
For International Women’s Day, DDW’s Diana Spencer celebrates some of the women in leadership making an impact on the drug discovery and life sciences sector. The life sciences sector has traditionally outperformed others when it comes to attracting women to its workforce.
XTalks
AUGUST 3, 2022
The drug is the first FDA approved oral suspension form of zonisamide. Hear about how the drug could help increase accessibility and flexibility for epilepsy patients and improve treatment adherence. Hear more about raising awareness about rare diseases like vitiligo and how it can help foster the development of new treatments.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 20, 2023
What are benefits of drug repurposing and why do clinical drug trials so often fail? Diana Spencer summarises the key messages from the ‘Drug Repurposing: Challenges and Opportunities’ Symposium held at the 19th World Congress of Basic & Clinical Pharmacology (WCP) 2023.
Advarra
AUGUST 16, 2022
Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinical trial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. Food and Drug Administration (FDA) approval.
pharmaphorum
DECEMBER 1, 2022
To ease this burden, the life sciences industry has been searching for ways to make clinical trials more accessible for patients and to drive participation numbers, increase participant diversity, and improve overall patient experience. Build a base in the community. Keep it simple. In fact, the opposite is true.
XTalks
MAY 16, 2023
The exact cause of pulmonary fibrosis is often unknown, and in such cases, it is referred to as idiopathic pulmonary fibrosis (IPF); however, certain factors can contribute to the development of pulmonary fibrosis, including environmental and occupational exposures, certain medications, autoimmune diseases and genetic predisposition.
XTalks
APRIL 26, 2021
After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease. Malaria Vaccine Phase II Trial.
Expert insights. Personalized for you.
98 
Let's personalize your content